HeartBeam’s Promising Future: Buy Rating Backed by Strategic Developments and Market Opportunities
I'm PortAI, I can summarize articles.
Bill Sutherland from Benchmark Co. reiterated a Buy rating for HeartBeam, maintaining an $8.00 price target. The company is nearing a second 510(k) clearance for its at-home arrhythmia assessment system, enhancing its market potential. Strategic partnerships and a promising financial model support this outlook. Roth MKM also reiterated a Buy rating with a $4.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments